Similar articles

• Cardiovascular health. Statin therapy reduces disease in healthy volunteers--but how, exactly?

  Couzin J. Couzin J. Science. 2008 Nov 14;322(5904):1039. doi: 10.1126/science.322.5904.1039. Science. 2008. PMID: 19008423 No abstract available.
• Rosuvastatin for cardiovascular prevention: too many uncertainties.

  [No authors listed] [No authors listed] Prescrire Int. 2009 Aug;18(102):176. Prescrire Int. 2009. PMID: 19746571
• Most would fail to benefit from JUPITER Intervention.

  Plonk WM Jr. Plonk WM Jr. J Am Coll Cardiol. 2009 Aug 18;54(8):744; author reply 744-5. doi: 10.1016/j.jacc.2009.04.069. J Am Coll Cardiol. 2009. PMID: 19679258 No abstract available.
• Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

  Ridker PM; JUPITER Study Group. Ridker PM, et al. Circulation. 2003 Nov 11;108(19):2292-7. doi: 10.1161/01.CIR.0000100688.17280.E6. Circulation. 2003. PMID: 14609996 Review. No abstract available.
• Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.

  de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, Okuyama H, Pavy B, Rabaeus M. de Lorgeril M, et al. Arch Intern Med. 2010 Jun 28;170(12):1032-6. doi: 10.1001/archinternmed.2010.184. Arch Intern Med. 2010. PMID: 20585068 Review.